Feeding Behavior

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Colorado TherapeuticsCO - Louisville

3 programs

Active Implicit PrimingN/A1 trial

Energy StimulusN/A1 trial

Repeated ExposureN/A

Active Trials

NCT02347527Completed92Est. Aug 2019

NCT04208256Completed63Est. Sep 2024

Human BioSciencesWV - Martinsburg

1 program

Longer meal durationN/A1 trial

Active Trials

NCT03127579Completed50Est. Dec 2017

Temple TherapeuticsNetherlands - Geleen

1 program

Repeated ExposureN/A1 trial

Active Trials

NCT05639361Unknown180Est. Jun 2024

Alliance PharmaceuticalsUK - Wiltshire

1 program

School-based water campaignN/A1 trial

Active Trials

NCT02996422Completed1,657Est. Jul 2020

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Temple TherapeuticsRepeated Exposure

Colorado TherapeuticsEnergy Stimulus

Alliance PharmaceuticalsSchool-based water campaign

Human BioSciencesLonger meal duration

Colorado TherapeuticsActive Implicit Priming

Clinical Trials (5)

Total enrollment: 2,042 patients across 5 trials

NCT05639361 Temple TherapeuticsRepeated Exposure

Healthy Starts: Repeated Exposure Pilot

Start: Apr 2023Est. completion: Jun 2024180 patients

N/AUnknown

NCT04208256 Colorado TherapeuticsEnergy Stimulus

Food Intake and the Adolescent Brain

Start: Dec 2019Est. completion: Sep 202463 patients

N/ACompleted

NCT02996422 Alliance PharmaceuticalsSchool-based water campaign

Appalachians Together Restoring the Eating Environment: Improving Healthy Diet in Rural Appalachian Kentucky

Start: Nov 2016Est. completion: Jul 20201,657 patients

N/ACompleted

NCT03127579 Human BioSciencesLonger meal duration

Family Meal Duration and Children's Eating Behavior

Start: Nov 2016Est. completion: Dec 201750 patients

N/ACompleted

NCT02347527 Colorado TherapeuticsActive Implicit Priming

Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals

Start: May 2013Est. completion: Aug 201992 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.